about
Headache in essential thrombocythaemiaAnti-platelet therapy: phosphodiesterase inhibitors.The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential ThrombocythemiaCurrent management of polycythemia veraAnagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologistsCyclic AMP signaling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin-dependent kinase inhibitor 1A (CDKN1A) transcriptional axis.Essential thrombocythaemia in children.Anagrelide: an update on its mechanisms of action and therapeutic potential.Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell culturesEssential thrombocythemia (ET): moving from palliation to cure.Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.A critical review of anagrelide therapy in essential thrombocythemia and related disorders.Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.Targeting phosphodiesterases in anti-platelet therapyAnagrelide: 20 years later.Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.Hemostatic defects in cancer patients.Anagrelide and Mutational Status in Essential Thrombocythemia.Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.Current perspective in agnogenic myeloid metaplasia.Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.Familial essential thrombocythemia.Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.n-Bu₄NI-catalyzed selective dual amination of sp³ C-H bonds: oxidative domino synthesis of imidazo[1,5-c]quinazolines on a gram-scale.Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
P2860
Q24629739-A5AA2D69-5B55-493C-9364-0210FA1EF349Q27687228-1ADFC85A-A5A5-4ED3-929F-78DCDC975F58Q28074777-E3596C0A-CF13-4619-8932-8223594D4B41Q28192595-A0DCB39E-55C3-4651-8092-0B327CAE58D6Q28307195-A89E3060-6E00-4AA2-A03C-63353A74BA9DQ30419048-C1FF2722-2E39-4F14-8AD6-E7C02464ABE1Q33801195-467B6C95-7F94-4FE1-8773-89E15E0D1C2FQ34549542-7C47FFAD-3305-42EB-8AC7-0E7843A6C3C5Q34559471-E36D112B-F90B-4113-A415-A385695B6560Q35022117-C0FC8FCE-AEEA-4D73-AC29-230DCA272DAEQ35841596-FEA13D22-94D1-4E00-89BF-FCBEAFB92D74Q36194626-70462784-5171-46A7-84FC-CD1C79D66C57Q36350472-60EFCCA3-6254-432C-B3E0-37D8212F0558Q36929627-C9127741-C22E-4D30-AC9A-0FFE9CB50467Q37357291-645BB387-ABEA-486A-89C3-C0F7F584F79FQ37810089-120DACEA-EBE7-4B7D-A90D-F759D3BEEC2DQ38420817-3D52B73D-4EB0-4C37-9B21-30A30875E74CQ39127942-C3107F5D-5E44-4B03-AF3A-C95D8DB48BBAQ39867043-8D0743A1-1D6A-43DA-97CF-C4A63D740888Q40647857-D19975E4-76C3-485C-935A-0001669ED147Q40953190-9A12B13F-A65E-4C0A-A034-CEC661ED52BAQ41253030-DE580971-32EE-41FD-9F2F-63A1C4D7C24EQ41253192-A07B5F25-B6B4-49A6-9CB8-A21DEDD8AD87Q41253215-49E29A06-8C11-44EA-A413-FCFC7778C7B8Q42685892-05117DA9-0628-4C5A-B60C-8334CA379314Q45002580-13C41C79-ED16-428B-A466-9B915DD48105Q48093627-E6993F4A-ABE6-4317-AB93-9A5F9F649B53Q49784463-D202A17E-EE92-4215-89DA-79992C6D5DB7Q53596367-35B963D1-EC23-4216-B779-125319A9E6ACQ53633458-19C89331-CE74-4D55-B1F0-DE0CA385697EQ54262553-EAFAF6F3-67C0-4088-8651-F0C433166DEE
P2860
description
1988 nî lūn-bûn
@nan
1988 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Anagrelide: a new drug for treating thrombocytosis.
@ast
Anagrelide: a new drug for treating thrombocytosis.
@en
type
label
Anagrelide: a new drug for treating thrombocytosis.
@ast
Anagrelide: a new drug for treating thrombocytosis.
@en
prefLabel
Anagrelide: a new drug for treating thrombocytosis.
@ast
Anagrelide: a new drug for treating thrombocytosis.
@en
P2093
P1476
Anagrelide: a new drug for treating thrombocytosis.
@en
P2093
J S Fleming
L A Solberg
L P Schacter
M N Silverstein
R C Knight
R M Petitt
P304
P356
10.1056/NEJM198805193182002
P407
P577
1988-05-01T00:00:00Z